ABSTRACT
Use of 18 
F-FET PET in pediatric brain tumors

INTRODUCTION
Primary tumors of the central nervous system (CNS) are one of the most common causes of cancer-related death in children (1) . The choice of antitumoral treatment depends upon tumor histology, tumor location and patient age and management of CNS tumors in this patient group to date remains challenging. Brain tumors in children and adolescents comprise a great variety of tumor entities of varying malignancy, such as pilocytic astrocytoma, diffuse astrocytic gliomas including glioblastoma, ependymoma, medulloblastoma and other CNS primitive neuroectodermal tumor types, as well as various other tumor types, e.g., craniopharyngioma and germ cell tumors. Tumor location is heterogeneous, and in many cases, proximity to critical or eloquent brain structures precludes complete and partial resection and allows for diagnostic (stereotactic) biopsy only.
Concerning diagnostic imaging, contrast-enhanced structural MRI alone cannot always distinguish neoplastic from benign intracranial lesions. Moreover, the differentiation of treatment effects, such as, e.g., radiation-induced changes, from recurrent and/or progressive disease may be difficult. In adult patients, PET using radiolabeled amino acids has been shown to improve diagnostic accuracy in patients with primary brain tumors, in particular gliomas (2, 3) . In FET PET uptake may, however, provide valuable additional diagnostic information due to differential kinetic patterns of tracer uptake in high-and low-grade glioma (11-13), a phenomenon not observed with 11 C-MET PET (14) . For example, the kinetic pattern of a highgrade glioma appears to be characterized by an early peak after injection within the first 20 min followed by a decrease of 18 F-FET uptake. In contrast, steadily increasing time-activity curves without identifiable peak of the tracer uptake are typical for low-grade gliomas (12, 13, (15) (16) (17) (18) (19) .
To date, experience with dynamic 18 F-FET PET in children and adolescents with brain tumors is limited and is based on single case reports (20) (21) (22) . Thus, the purpose of this study was to evaluate the diagnostic accuracy of this method in this particular age group.
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MATERIALS AND METHODS
Ethics
This study represents a retrospective evaluation of a series of medically necessary 18 F-FET PET investigations in children and adolescents that were performed as compassionate use. The study was approved by the local ethics committee. There was no conflict with the declaration of Helsinki. All investigations were carried out on the expressed request and written documentation of the responsible pediatricians and in full agreement with the legal guardians. In all cases, there was no further diagnostic alternative except potentially life-threatening invasive procedures.
Based on the clinical experience in several thousand 18 F-FET PET investigations in adult patients without any side effects and based on the fact that no side effects or risks (except radiation burden) were to be expected due to the extremely low concentration of this non-toxic artificial amino acid, the risk of disease was judged as outweighing the risk of investigation.
Patients
Forty-eight children and adolescents ≤ 18 years of age with brain tumors who had received As reported before, the threshold of age to differentiate between children and adolescents was set at 15 years (4). In the literature, a clear definition of an adolescent is not available; therefore, the threshold of 15 years was set in the middle of the period of life between 10 and 20 years, which is the current definition of adolescence by the World Health Organization (WHO). At the time of 18 F-FET PET imaging, 35 of the 48 patients (73%) studied were younger than 15 years.
PET Imaging with 18 F-FET and Data Analysis
The amino acid 18 F-FET was produced via nucleophilic 18 F-fluorination with a specific radioactivity of > 200 GBq/μmol as described previously (23) . The radiochemical yield of the tracer was about 60-65% at a radiochemical purity > 98%. The tracer was administered as isotonic neutral solution. All patients remained fasted for at least 6 h before PET scanning.
Dynamic PET studies were acquired up to 50 min after intravenous injection of F-FET uptake in the tumor was determined using a two-dimensional autocontouring process using a tumor-to-brain ratio (TBR) ≥ 1.6. This cut-off is based on a biopsy-controlled study in cerebral gliomas where a lesion-to-brain ratio of 1.6 separated best tumoral from peritumoral tissue (26). 
Statistical Analysis
Descriptive statistics are provided as mean and standard deviation. To compare two different groups, the Student t test for independent samples was used. The Mann-Whitney rank sum test was used when variables were not distributed normally. P values of less than 0.05 were considered significant.
The diagnostic accuracy of the TBR mean and TBR max of 
RESULTS
Patients with Newly Diagnosed Cerebral Lesions
In the 26 patients with newly diagnosed cerebral lesions, a total of 26 PET scans were performed. images without histological confirmation (n=4), one of which was confirmed as being due to a neoplastic lesion while 3 were proven as non-neoplastic lesions on follow-up (Supplemental Table 1 ). Diagnoses were confirmed histologically in 20 of 26 patients (77%). In 6 patients the diagnosis of a brain tumor / benign lesion was determined clinically (i.e., stable/unstable clinical course, follow-up MRI findings).
In this group of patients with newly diagnosed cerebral lesions, ROC analysis revealed that the highest accuracy (77%) to detect neoplastic tissue (19 of 26 patients) was obtained when TBR max was ≥ 1.7 (AUC, 0.80 ± 0.09; sensitivity, 79%; specificity, 71%, PPV, 88%; P = 0.02) (Supplemental Table 5 ). A corresponding patient example is presented in Figure 1A . The diagnostic accuracy was slightly lower when the TBR mean was used as a parameter. The inclusion of kinetic parameters yielded no significant result regarding the differentiation of neoplastic from non-neoplastic lesions.
Patients with Suspicion of Tumor Progression or Recurrence
Eighteen Table 2 ). In 13 patients absence or presence of tumor progression/recurrence was determined clinically (i.e., stable/unstable clinical course, follow-up MRI findings, overall survival, treatment change) (Supplemental Table 2 ). In 13 of 24 cases, tumor progression or recurrence could be diagnosed.
For diagnosing tumor progression or recurrence, a high diagnostic accuracy was achieved when the TBR mean and TBR max were used (79%). Highest accuracy (82%) was, however, obtained when decision was based on kinetic parameters, i.e., when curve patterns 2 or 3 were present (sensitivity, 75%; specificity, 90%, PPV, 90%; P = 0.004) (Supplemental Table 5 ). A corresponding patient example is presented in Figure 1B and 1C. 
Use of 18 F-FET PET for Monitoring of Chemotherapy Effects
Use of 18 F-FET PET for the Detection of Residual Tumor Tissue After Resection
In order to detect residual tumor tissue after tumor resection, 10 patients were investigated by early postoperative MRI within the first 48 h and Supplemental Table 4 ).
DISCUSSION
Our findings suggest that imaging parameters derived from Furthermore, first experiences in a small number of pediatric brain tumor patients in our study demonstrate that 18 F-FET PET may be helpful for monitoring the effects of chemotherapy in malignant brain tumors. In the majority of these patients treated with chemotherapy we observed a reduction of amino acid uptake. Our findings suggest that this finding is related to a stable clinical course. However, this observation should be re-evaluated in a higher number of pediatric patients with the same histology and chemotherapy. Moreover, 18 F-FET PET appears to be helpful to determine the residual tumor volume after brain tumor resection and may serve as a valuable tool for optimal planning of the further treatment strategy, e.g., decision for re-resection, adjuvant radiotherapy. The reliability of One may argue that the results of our study are based upon a relatively small number of investigated patients with a large variety of distinct entities and that our results should hence be treated with caution and confirmed in a larger series of patients. However, the results of this study are based on 48 patients and 69 observations which constitutes to date the largest sample of children or adolescents brain tumors studied using static and dynamic 
